Teladoc Health, Inc. (FRA:4LL)
Germany · Delayed Price · Currency is EUR 4.587
-0.113 (-2.40%)
At close: Jan 30, 2026
Teladoc Health Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 2,528 | 2,570 | 2,602 | 2,407 | 2,033 | 1,094 | |
Revenue Growth (YoY) | -2.37% | -1.26% | 8.13% | 18.41% | 85.81% | 97.71% |
Cost of Revenue | 763.47 | 751.27 | 760.03 | 743.99 | 650.26 | 390.83 |
Gross Profit | 1,765 | 1,818 | 1,842 | 1,663 | 1,382 | 703.13 |
Selling, General & Admin | 1,301 | 1,346 | 1,367 | 1,301 | 1,105 | 886.88 |
Research & Development | 283.07 | 307.27 | 348.52 | 333.63 | 311.88 | 164.94 |
Amortization of Goodwill & Intangibles | 345.27 | 363.37 | 325.93 | 234.72 | 195.3 | - |
Operating Expenses | 1,943 | 2,027 | 2,053 | 1,880 | 1,621 | 1,121 |
Operating Income | -178.59 | -208.79 | -210.5 | -217.47 | -238.99 | -418.19 |
Interest Expense | -21.61 | -23.8 | -22.28 | -21.94 | -81.14 | -59.95 |
Interest & Investment Income | 44.05 | 57.07 | 46.78 | 12.67 | 0.78 | - |
Currency Exchange Gain (Loss) | - | - | - | - | -0.81 | - |
Other Non Operating Income (Expenses) | 2.65 | -6.04 | 4.45 | -0.86 | - | -0.55 |
EBT Excluding Unusual Items | -153.5 | -181.56 | -181.56 | -227.6 | -320.17 | -478.68 |
Merger & Restructuring Charges | -24.82 | -22.1 | -38.05 | -23.04 | -26.64 | -88.24 |
Impairment of Goodwill | -71.76 | -790 | - | -13,403 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | 5.9 | - |
Asset Writedown | - | - | - | -9.9 | - | - |
Other Unusual Items | - | - | - | - | -43.75 | -9.08 |
Pretax Income | -250.08 | -993.65 | -219.61 | -13,663 | -384.66 | -575.99 |
Income Tax Expense | -26.5 | 7.59 | 0.76 | -3.81 | 44.14 | -90.86 |
Net Income | -223.59 | -1,001 | -220.37 | -13,660 | -428.79 | -485.14 |
Net Income to Common | -223.59 | -1,001 | -220.37 | -13,660 | -428.79 | -485.14 |
Shares Outstanding (Basic) | 175 | 171 | 165 | 161 | 157 | 91 |
Shares Outstanding (Diluted) | 175 | 171 | 165 | 161 | 157 | 91 |
Shares Change (YoY) | 3.59% | 3.64% | 1.93% | 2.88% | 73.40% | 25.98% |
EPS (Basic) | -1.28 | -5.87 | -1.34 | -84.60 | -2.73 | -5.36 |
EPS (Diluted) | -1.28 | -5.87 | -1.34 | -84.60 | -2.73 | -5.36 |
Free Cash Flow | 280.11 | 282.89 | 338.56 | 172.81 | 185.46 | -57.54 |
Free Cash Flow Per Share | 1.60 | 1.66 | 2.06 | 1.07 | 1.18 | -0.64 |
Gross Margin | 69.80% | 70.76% | 70.80% | 69.09% | 68.01% | 64.27% |
Operating Margin | -7.06% | -8.13% | -8.09% | -9.04% | -11.76% | -38.23% |
Profit Margin | -8.84% | -38.96% | -8.47% | -567.53% | -21.09% | -44.35% |
Free Cash Flow Margin | 11.08% | 11.01% | 13.01% | 7.18% | 9.12% | -5.26% |
EBITDA | 16.17 | 31.72 | 43.61 | -7.54 | -31.42 | -354.49 |
EBITDA Margin | 0.64% | 1.23% | 1.68% | -0.31% | -1.55% | -32.40% |
D&A For EBITDA | 194.76 | 240.51 | 254.11 | 209.93 | 207.57 | 63.69 |
EBIT | -178.59 | -208.79 | -210.5 | -217.47 | -238.99 | -418.19 |
EBIT Margin | -7.06% | -8.13% | -8.09% | -9.04% | -11.76% | -38.23% |
Advertising Expenses | - | 693.21 | 673.55 | 609.45 | 397.77 | 199.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.